All News

A colorectal cancer survivor shares what life with an ostomy is really like, offering advice and reassurance for patients adjusting after surgery.

CURE was live on site at the the 19th Annual New York GU Cancers Congress®, where we spoke with Dr. Ulka Vaishampayan on the topic of kidney cancer.

Dr. Anastasia Tousimis explores the feasibility, risks and surgical techniques for performing NSM in radiated patients to ensure oncologic safety.

That’s what I need to remember: Not made-up scenarios, but that if I’m open, truly open, to whatever life has in store, it will be OK.

Keytruda plus weekly paclitaxel improved overall and progression-free survival in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

A study of 922 patients shows the Aida test predicts 10-year recurrence risk and helps guide radiation decisions for invasive breast cancer.

A structured exercise program may reduce cognitive decline, often referred to as “chemo brain,” in patients receiving chemotherapy for the first time.

Dr. Ajay K. Nooka, highlights how the evolution of therapy has moved the goalposts from simply achieving remission to pursuing a measurable cure.

Dr. Sandeep Kunwar explained that getting drugs into the brain is a major hurdle for glioblastoma, as the blood-brain barrier blocks most treatments.

An expert explains how immunotherapy, targeted therapy and tumor testing are expanding treatment options for patients with gynecologic cancers.

Preliminary INVINCIBLE-4 study data shows INT230-6 plus standard care may increase pathological complete response rates and improve patient safety.

On March 22, individuals and organizations across the country will recognize National Health Care Rights Day.

Dr. Matthew Galsky discusses the background of the KEYNOTE-B15 study, the key results and what these findings could mean for patients.

Forget the outdated image of colon cancer as a disease for the elderly. The new, and increasingly common, faces of this disease are pictured here.

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves survival in platinum-resistant ovarian cancer.

No matter how hard this is, I still recommend clinical trials. Not as a last resort, but as an important option when weighing treatment choices. I don’t know what choice I’ll make, but I’m thankful I’m still here to have that choice.

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care.

Only about 0.01% of biologic drugs reach glioblastoma tumors, but convection-enhanced delivery bypasses the barrier to deliver therapy directly to the brain.

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

During Kidney Cancer Awareness Month, Dr. Eric Singer shares warning signs, risk factors and when younger adults should speak with a doctor about kidney health.

Dr. Jonathan W. Friedberg says long-term data show 42% of treated follicular lymphoma patients achieved functional cure with chemoimmunotherapy.

Dr. Kevin Kalinsky discusses common side effects associated with the FDA-approved combination of Enhertu and Perjeta for breast cancer.

Black Medicare patients with early-stage NSCLC continue to get surgery and radiation at lower rates than White patients, showing persistent treatment gaps.

Phase 2 interim data show NDV-01 produced high response rates and encouraging safety in patients with non–muscle-invasive bladder cancer.

The phase 3 persevERA study of giredestrant plus Ibrance missed its PFS goal, though positive data from other trials supports the drug.

FDA declined approval of retifanlimab for metastatic non–small cell lung cancer due to manufacturing issues at a third-party facility, not safety concerns.

Fifteen-year follow-up from the S0016 trial found over one-third of patients with follicular lymphoma treated with chemoimmunotherapy had no progression.